- Date 23 May 2012
- Documents : 3
- History
- (Restricted access link)
Listen
DIHYDROERGOTAMINE AMDIPHARM
-
Opinions on drugs -
Posted on
Mar 19 2013
Reason for request
Re-assessment of Actual Benefit of proprietary medicinal products based on dihydroergotamine, in accordance with Article R 163-21 of the social security code.
-
Clinical Benefit
| Moderate |
The actual benefit of the medicinal product administered via injectionis moderate in the treatment of acute migraine. |
| Insufficient |
The actual benefit of the proprietary medicinal products administered orally is insufficient in the preventative treatment of migraine. |
English version
Contact Us
Évaluation des médicaments
